Sangjoon Choi1, So-Woon Kim2, Hyun-Soo Kim3. 1. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea hyun-soo.kim@samsung.com sowoonkim86@gmail.com. 3. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; hyun-soo.kim@samsung.com sowoonkim86@gmail.com.
Abstract
BACKGROUND/AIM: Invasive stratified mucin-producing carcinoma (ISMC) of the uterine cervix has been reported to be more aggressive than other subtypes of endocervical adenocarcinoma. We investigated the clinicopathological and molecular characteristics of eight ISMCs. PATIENTS AND METHODS: We reviewed the electronic medical records and pathology slides of eight patients with ISMC and conducted programmed death-ligand 1 (PD-L1) immunostaining and targeted sequencing. RESULTS: The patients were between 31 and 54 years. Six tumors were pure ISMCs, and two showed co-existing squamous cell carcinoma and usual-type endocervical adenocarcinoma. Lymph node metastases were detected in three cases. Three patients developed distant metastases to the adnexa, lungs, inguinal lymph nodes, and small intestine. Two patients experienced disease progression, and three developed postoperative local recurrences. All tumors showed PD-L1 over-expression, with a mean combined positive score of 73.8 (range=30-100). One tumor harbored erb-b2 receptor tyrosine kinase 2 amplification. CONCLUSION: ISMC of the uterine cervix exhibits a high risk of recurrence, metastasis, and resistance to chemoradiation therapy. PD-L1 over-expression was consistently observed in all ISMCs. This finding raises the possibility that patients with ISMC may benefit from PD-L1 immunotherapy. Copyright
BACKGROUND/AIM: Invasive stratified mucin-producing carcinoma (ISMC) of the uterine cervix has been reported to be more aggressive than other subtypes of endocervical adenocarcinoma. We investigated the clinicopathological and molecular characteristics of eight ISMCs. PATIENTS AND METHODS: We reviewed the electronic medical records and pathology slides of eight patients with ISMC and conducted programmed death-ligand 1 (PD-L1) immunostaining and targeted sequencing. RESULTS: The patients were between 31 and 54 years. Six tumors were pure ISMCs, and two showed co-existing squamous cell carcinoma and usual-type endocervical adenocarcinoma. Lymph node metastases were detected in three cases. Three patients developed distant metastases to the adnexa, lungs, inguinal lymph nodes, and small intestine. Two patients experienced disease progression, and three developed postoperative local recurrences. All tumors showed PD-L1 over-expression, with a mean combined positive score of 73.8 (range=30-100). One tumor harbored erb-b2 receptor tyrosine kinase 2 amplification. CONCLUSION: ISMC of the uterine cervix exhibits a high risk of recurrence, metastasis, and resistance to chemoradiation therapy. PD-L1 over-expression was consistently observed in all ISMCs. This finding raises the possibility that patients with ISMC may benefit from PD-L1 immunotherapy. Copyright
Authors: Danny Rischin; Marta Gil-Martin; Antonio González-Martin; Irene Braña; June Y Hou; Daniel Cho; Gerald S Falchook; Silvia Formenti; Salma Jabbour; Kathleen Moore; Aung Naing; Kyriakos P Papadopoulos; Joaquina Baranda; Wen Fury; Minjie Feng; Elizabeth Stankevich; Jingjin Li; N Alice Yama-Dang; Suk-Young Yoo; Israel Lowy; Melissa Mathias; Matthew G Fury Journal: Gynecol Oncol Date: 2020-09-09 Impact factor: 5.482
Authors: Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch Journal: Cancer Date: 2013-08-23 Impact factor: 6.860